Research ArticleOriginal Article
Open Access

Association of XRCC1 Trp194 allele with risk of breast cancer, and Ki67 protein status in breast tumor tissues

Chiya Jalali, Bayazid Ghaderi, Sabrieh Amini, Mohammad Abdi and Daem Roshani
Saudi Medical Journal June 2016, 37 (6) 624-630; DOI: https://doi.org/10.15537/smj.2016.6.13540

References

  1. ↵
    1. Benson JR,
    2. Jatoi I
    (2012) The global breast cancer burden. Future Oncol 8:697–702.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Mousavi SM1,
    2. Montazeri A,
    3. Mohagheghi MA,
    4. Jarrahi AM,
    5. Harirchi I,
    6. Najafi M,
    7. et al.
    (2007) Breast cancer in Iran: an epidemiological review. Breast J 13:383–391.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Jafari-Koshki T,
    2. Schmid VJ,
    3. Mahaki B
    (2014) Trends of breast cancer incidence in Iran during 2004-2008: a Bayesian space-time model. Asian Pac J Cancer Prev 15:1557–1561.
    OpenUrl
  4. ↵
    1. Reyna C,
    2. Lee MC
    (2014) Breast cancer in young women: special considerations in multidisciplinary care. J Multidiscip Healthc 7:419–429.
    OpenUrl
  5. ↵
    1. Toriola AT,
    2. Colditz GA
    (2013) Trends in breast cancer incidence and mortality in the United States: implications for prevention. Breast Cancer Res Treat 138:665–673.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Gannon LM,
    2. Cotter MB,
    3. Quinn CM
    (2013) The classification of invasive carcinoma of the breast. Expert Rev Anticancer Ther 13:941–954.
    OpenUrl
  7. ↵
    1. Rakha EA,
    2. Ellis IO
    (2011) Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol 18:255–267.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Cleator S,
    2. Heller W,
    3. Coombes RC
    (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Dai L,
    2. Wang K,
    3. Zhang J,
    4. Lv Q,
    5. Wu X,
    6. Wang Y
    (2009) XRCC1 gene polymorphisms and esophageal squamous cell carcinoma risk in Chinese population: A meta-analysis of case-control studies. Int J Cancer 125:1102–11029.
    OpenUrlPubMed
  10. ↵
    1. Yu H,
    2. Fu C,
    3. Wang J,
    4. Xue H,
    5. Xu B
    (2011) Interaction between XRCC1 polymorphisms and intake of long-term stored rice in the risk of esophageal squamous cell carcinoma: a case-control study. Biomed Environ Sci 24:268–274.
    OpenUrlPubMed
  11. ↵
    1. Hu Z,
    2. Ma H,
    3. Chen F,
    4. Wei Q,
    5. Shen H
    (2005) XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev 14:1810–1818.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Vodicka P,
    2. Stetina R,
    3. Polakova V,
    4. Tulupova E,
    5. Naccarati A,
    6. Vodickova L,
    7. et al.
    (2007) Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis 28:657–664.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Takeshita H,
    2. Fujihara J,
    3. Yasuda T,
    4. Kimura-Kataoka K
    (2014) Worldwide distribution of four snps in x-ray and repair and cross-complementing group 1 (XRCC1). Clin Transl Sci 8:347–350.
    OpenUrl
  14. ↵
    1. Wang Y,
    2. Spitz MR,
    3. Zhu Y,
    4. Dong Q,
    5. Shete S,
    6. Wu X
    (2003) From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst) 2:901–908.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Metsola K,
    2. Kataja V,
    3. Sillanpää P,
    4. Siivola P,
    5. Heikinheimo L,
    6. Eskelinen M,
    7. et al.
    (2005) XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study. Breast Cancer Res 7:R987–R997.
    OpenUrlCrossRefPubMedWeb of Science
    1. Pachkowski BF,
    2. Winkel S,
    3. Kubota Y,
    4. Swenberg JA,
    5. Millikan RC,
    6. Nakamura J
    (2006) XRCC1 genotype and breast cancer: functional studies and epidemiologic data show interactions between XRCC1 codon 280 His and smoking. Cancer Res 66:2860–2868.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Patel AV,
    2. Calle EE,
    3. Pavluck AL,
    4. Feigelson HS,
    5. Thun MJ,
    6. Rodriguez C
    (2005) A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk. Breast Cancer Res 7:R1168–R1173.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Macías-Gómez NM,
    2. Peralta-Leal V,
    3. Meza-Espinoza JP,
    4. Gutiérrez-Angulo M,
    5. Durán-González J,
    6. Ramírez-González JM,
    7. et al.
    (2015) Polymorphisms of the XRCC1 gene and breast cancer risk in the Mexican population. Fam Cancer 14:349–354.
    OpenUrl
  19. ↵
    1. Saadat M,
    2. Kohan L,
    3. Omidvari S
    (2008) Genetic polymorphisms of XRCC1 (codon 399) and susceptibility to breast cancer in Iranian women, a case-control study. Breast Cancer Res Treat 111:549–553.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Elston CW,
    2. Ellis IO
    (2002) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41:154–161.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Edge S,
    2. Byrd DR,
    3. Compton CC,
    4. Fritz AG,
    5. Greene FL,
    6. Trotti A
    , eds (2010) AJCC cancer staging manual (Springer-Verlag, New York (NY)), 7th ed.
  22. ↵
    1. Chambers JT,
    2. Carcangiu ML,
    3. Voynick IM,
    4. Schwartz PE
    (1990) Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol 94:255–260.
    OpenUrlCrossRefPubMed
    1. Carcangiu ML,
    2. Chambers JT,
    3. Voynick IM,
    4. Pirro M,
    5. Schwartz PE
    (1990) Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations. Am J Clin Pathol 94:247–254.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Ahmadi A,
    2. Poorfathollah AA,
    3. Aghaiipour M,
    4. Rezaei M,
    5. Nikoo-ghoftar M,
    6. Abdi M,
    7. et al.
    (2014) Diagnostic value of CD117 in differential diagnosis of acute leukemias. Tumor Biology 35:6763–6768.
    OpenUrl
  25. ↵
    1. Maroofi F,
    2. Amini S,
    3. Roshani D,
    4. Ghaderi B,
    5. Abdi M
    (2015) Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients. Tumor Biology 36:2863–2868.
    OpenUrl
  26. ↵
    1. Salimizand H,
    2. Amini S,
    3. Abdi M,
    4. Ghaderi B,
    5. Azadi N-A
    (2016) Concurrent effects of ABCB1, C3435T, ABCG2, C421A and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Tumor Biology 37:791–798.
    OpenUrl
  27. ↵
    1. Ghafouri H,
    2. Ghaderi B,
    3. Amini S,
    4. Nikkhoo B,
    5. Abdi M,
    6. Hoseini A
    (Dec, 2015) Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer. Tumour Biol, 1–6.
  28. ↵
    1. Bu T,
    2. Liu L,
    3. Sun Y,
    4. Zhao L,
    5. Peng Y,
    6. Zhou S,
    7. et al.
    (2014) XRCC1 Arg399Gln polymorphism confers risk of breast cancer in American population: a meta-analysis of 10846 cases and 11723 controls. PLoS One 9:86086.
    OpenUrl
  29. ↵
    1. Tengstrom M,
    2. Mannermaa A,
    3. Kosma VM,
    4. Hirvonen A,
    5. Kataja V
    (2014) XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer. Anticancer Res 34:3031–3037.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Feng YZ,
    2. Liu YL,
    3. He XF,
    4. Wei W,
    5. Shen XL,
    6. Xie DL
    (2014) Association between the XRCC1 Arg194Trp polymorphism and risk of cancer: evidence from 201 case-control studies. Tumour Biol 35:10677–97.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Ginsberg G,
    2. Angle K,
    3. Guyton K,
    4. Sonawane B
    (2011) Polymorphism in the DNA repair enzyme XRCC1: utility of current database and implications for human health risk assessment. Mutat Res 727:1–15.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Przybylowska-Sygut K,
    2. Stanczyk M,
    3. Kusinska R,
    4. Kordek R,
    5. Majsterek I
    (2013) Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer. Clin Breast Cancer 13:61–68.
    OpenUrlPubMed
  33. ↵
    1. Smith TR,
    2. Miller MS,
    3. Lohman K,
    4. et al.
    (2003) Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett 190:183–190.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Sliwinski T,
    2. Krupa R,
    3. Wisniewska-Jarosinska M,
    4. Lech J,
    5. Morawiec Z,
    6. Chojnacki J,
    7. et al.
    (2008) No association between the Arg194Trp and Arg399Gln polymorphisms of the XRCC1 gene and colorectal cancer risk and progression in a Polish population. Exp Oncol 30:253–254.
    OpenUrlPubMed
  35. ↵
    1. Au WW,
    2. Salama SA,
    3. Sierra-Torres CH
    (2003) Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 111:1843–1850.
    OpenUrlPubMedWeb of Science
  36. ↵
    1. Tuimala J,
    2. Szekely G,
    3. Wikman H,
    4. Järventaus H,
    5. Hirvonen A,
    6. Gundy S,
    7. et al.
    (2004) Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: effects on levels of sister chromatid exchanges and chromosomal aberrations. Mutat Res 554:319–333.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Dufloth RM,
    2. Arruda A,
    3. Heinrich JK,
    4. Schmitt F,
    5. Zeferino LC
    (2008) The investigation of DNA repair polymorphisms with histopathological characteristics and hormone receptors in a group of Brazilian women with breast cancer. Genet Mol Res 7:574–582.
    OpenUrlPubMed
  38. ↵
    1. Scholzen T,
    2. Gerdes J
    (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    1. Gissi DB,
    2. Gabusi A,
    3. Servidio D,
    4. Cervellati F,
    5. Montebugnoli L
    (2015) Predictive role of p53 protein as a single marker or associated with ki67 antigen in oral leukoplakia: A retrospective longitudinal study. Open Dent J 9:41–45.
    OpenUrl
  40. ↵
    1. Hsieh LL,
    2. Chien HT,
    3. Chen IH,
    4. Liao CT,
    5. Wang HM,
    6. Jung SM,
    7. et al.
    (2003) The XRCC1 399Gln polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 12:439–443.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section